GRI Bio Presents Preclinical Data From Pipeline Of NKT Cell Modulators In Development For Systemic Lupus Erythematosus
Data presented at the 14th International Congress on Autoimmunity
Encouraging preclinical data observed to date on par with OFEV® (nintedanib),
a leading tyrosine kinase inhibitor with 2025 projected sales of $5 billion1
Company targeting IND filing for GRI-0803 in Q3 2024 with topline data expected Q4 2024